Abstract
Introduction: Breast cancer is the second most common cause of cancer death in females, and 30% of these patients are over the age of 70 years. Studies have shown deviation from the standard treatment paradigms in the elderly, especially in regard to radiation treatment. Methods: We performed a retrospective chart review on 118 patients over the age of 70 years diagnosed with breast cancer and pathologically proven axillary disease over an 8-year period at an urban academic hospital to examine which patient factors influenced radiotherapy. Results: Increasing patient age was associated with a decrease in the probability of receiving radiotherapy, while HER2-negative patients were more likely to receive radiation. Neither race, number of coexisting medical conditions, or insurance status showed any influence on radiation treatment. Conclusion: Patient age has a significant influence if elderly patients with axillary disease receive radiotherapy. Further investigation and validation are needed to understand why chronological age rather than biological age influences treatment modalities.
References
1.
American Cancer Society
. (2018
). Cancer Facts & Figures 2018. 2018. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html. Accessed February 14, 2018.2.
Tesarova
P
. Breast cancer in the elderly-Should it be treated differently?
Rep Pract Oncol Radiother
. 2012
Jul
;18
(1
):26
–33
.
[PubMed]
1507-13673.
Karuturi
M
, VanderWalde
N
, Muss
H
. Approach and management of breast cancer in the elderly
. Clin Geriatr Med
. 2016
Feb
;32
(1
):133
–53
.
[PubMed]
0749-06904.
National Cancer Institute
. SEER cancer statistics factsheets: breast cancer.
2015
. http://seer.cancer.gov/statfacts/html/breast.html. Accessed August 5, 2017.5.
R Core Team
. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2016
. https://www.R-project.org. Accessed June 3, 2017.6.
Chesney
TR
, Yin
JX
, Rajaee
N
, Tricco
AC
, Fyles
AW
, Acuna
SA
, et al. Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: A systematic review and meta-analysis
. Radiother Oncol
. 2017
Apr
;123
(1
):1
–9
.
[PubMed]
0167-81407.
Diab
SG
, Elledge
RM
, Clark
GM
. Tumor characteristics and clinical outcome of elderly women with breast cancer
. J Natl Cancer Inst
. 2000
Apr
;92
(7
):550
–6
.
[PubMed]
0027-88748.
Gennari
R
, Curigliano
G
, Rotmensz
N
, Robertson
C
, Colleoni
M
, Zurrida
S
, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients
. Cancer
. 2004
Sep
;101
(6
):1302
–10
.
[PubMed]
0008-543X9.
Rodrigues
NA
, Dillon
D
, Carter
D
, Parisot
N
, Haffty
BG
. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women
. Cancer
. 2003
Mar
;97
(6
):1393
–403
.
[PubMed]
0008-543X10.
Davies
C
, Godwin
J
, Gray
R
, Clarke
M
, Cutter
D
, Darby
S
, et al.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
. Lancet
. 2011
Aug
;378
(9793
):771
–84
.
[PubMed]
0140-673611.
Fisher
B
, Costantino
J
, Redmond
C
, Poisson
R
, Bowman
D
, Couture
J
, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
. N Engl J Med
. 1989
Feb
;320
(8
):479
–84
.
[PubMed]
0028-479312.
Giordano
SH
, Hortobagyi
GN
, Kau
SW
, Theriault
RL
, Bondy
ML
. Breast cancer treatment guidelines in older women
. J Clin Oncol
. 2005
Feb
;23
(4
):783
–91
.
[PubMed]
0732-183X13.
Hughes
KS
, Schnaper
LA
, Bellon
JR
, Cirrincione
CT
, Berry
DA
, McCormick
B
, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343
. J Clin Oncol
. 2013
Jul
;31
(19
):2382
–7
.
[PubMed]
0732-183X14.
Martelli
G
, Boracchi
P
, De Palo
M
, Pilotti
S
, Oriana
S
, Zucali
R
, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up
. Ann Surg
. 2005
Jul
;242
(1
):1
–6
.
[PubMed]
0003-493215.
Martelli
G
, Miceli
R
, Daidone
MG
, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up.
Annals of Surgical Oncology. 2011
. Jan;18(1):125-33. 16.
Darby
SC
, Ewertz
M
, McGale
P
, Bennet
AM
, Blom-Goldman
U
, Brønnum
D
, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer
. N Engl J Med
. 2013
Mar
;368
(11
):987
–98
.
[PubMed]
0028-479317.
Hansen
TM
, Zellars
RC
. Treatment Minimization in Older Patients With Early-Stage Breast Cancer
. Cancer J
. 2017
Jul/Aug
;23
(4
):231
–7
.
[PubMed]
1528-911718.
Ott
OJ
, Strnad
V
, Hildebrandt
G
, Kauer-Dorner
D
, Knauerhase
H
, Major
T
, et al.; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO)
. GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance
. Radiother Oncol
. 2016
Jul
;120
(1
):119
–23
.
[PubMed]
0167-814019.
Shah
C
, Badiyan
S
, Ben Wilkinson
J
, Vicini
F
, Beitsch
P
, Keisch
M
, et al. Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite(®) breast brachytherapy registry trial
. Ann Surg Oncol
. 2013
Oct
;20
(10
):3279
–85
.
[PubMed]
1068-926520.
Livi
L
, Meattini
I
, Marrazzo
L
, Simontacchi
G
, Pallotta
S
, Saieva
C
, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial
. Eur J Cancer
. 2015
Mar
;51
(4
):451
–63
.
[PubMed]
0959-804921.
Rabinovitch
R
, Moughan
J
, Vicini
F
, Pass
H
, Wong
J
, Chafe
S
, et al. Long-term update of NRG Oncology RTOG 0319: a phase 1 and 2 trial to evaluate 3-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for stage I and II breast carcinoma
. Int J Radiat Oncol Biol Phys
. 2016
Dec
;96
(5
):1054
–9
.
[PubMed]
0360-301622.
White
J
, Winter
K
, Kuske
RR
, Bolton
JS
, Arthur
DW
, Scroggins
T
, et al. Long-term cancer outcomes from study NRG Oncology/RTOG 9517: a phase 2 study of accelerated partial breast irradiation with multicatheter brachytherapy after lumpectomy for early- stage breast cancer
. Int J Radiat Oncol Biol Phys
. 2016
Aug
;95
(5
):1460
–5
.
[PubMed]
0360-301623.
Smith
BD
, Arthur
DW
, Buchholz
TA
, Haffty
BG
, Hahn
CA
, Hardenbergh
PH
, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO)
. Int J Radiat Oncol Biol Phys
. 2009
Jul
;74
(4
):987
–1001
.
[PubMed]
0360-301624.
Goodwin
JS
, Hunt
WC
, Samet
JM
. Determinants of cancer therapy in elderly patients
. Cancer
. 1993
Jul
;72
(2
):594
–601
.
[PubMed]
0008-543X25.
Silliman
RA
, Troyan
SL
, Guadagnoli
E
, Kaplan
SH
, Greenfield
S
. The impact of age, marital status, and physician-patient interactions on the care of older women with breast carcinoma
. Cancer
. 1997
Oct
;80
(7
):1326
–34
.
[PubMed]
0008-543X26.
Silliman
RA
, Guadagnoli
E
, Weitberg
AB
, Mor
V
. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients
. J Gerontol
. 1989
Mar
;44
(2
):M46
–50
.
[PubMed]
0022-142227.
Mandelblatt
JS
, Hadley
J
, Kerner
JF
, Schulman
KA
, Gold
K
, Dunmore-Griffith
J
, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences
. Cancer
. 2000
Aug
;89
(3
):561
–73
.
[PubMed]
0008-543X28.
Fyles
AW
, McCready
DR
, Manchul
LA
, Trudeau
ME
, Merante
P
, Pintilie
M
, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer
. N Engl J Med
. 2004
Sep
;351
(10
):963
–70
.
[PubMed]
0028-479329.
Pötter
R
, Gnant
M
, Kwasny
W
, Tausch
C
, Handl-Zeller
L
, Pakisch
B
, et al.; Austrian Breast and Colorectal Cancer Study Group
. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer
. Int J Radiat Oncol Biol Phys
. 2007
Jun
;68
(2
):334
–40
.
[PubMed]
0360-301630.
Sautter-Bihl
ML
, Sedlmayer
F
, Budach
W
, Dunst
J
, Feyer
P
, Fietkau
R
, et al. When are breast cancer patients old enough for the quitclaim of local control?
Strahlenther Onkol
. 2012
Dec
;188
(12
):1069
–73
.
[PubMed]
0179-715831.
Matuschek
C
, Bölke
E
, Haussmann
J
, Mohrmann
S
, Nestle-Krämling
C
, Gerber
PA
, et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials
. Radiat Oncol
. 2017
Mar
;12
(1
):60
.
[PubMed]
1748-717X32.
Blamey
RW
, Bates
T
, Chetty
U
, Duffy
SW
, Ellis
IO
, George
D
, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial
. Eur J Cancer
. 2013
Jul
;49
(10
):2294
–302
.
[PubMed]
0959-804933.
Budach
W
, Bölke
E
, Kammers
K
, Gerber
PA
, Nestle-Krämling
C
, Matuschek
C
. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update
. Radiat Oncol
. 2015
Dec
;10
(1
):258
.
[PubMed]
1748-717X34.
Whelan
TJ
, Olivotto
IA
, Parulekar
WR
, Ackerman
I
, Chua
BH
, Nabid
A
, et al.; MA.20 Study Investigators
. Regional Nodal Irradiation in Early-Stage Breast Cancer
. N Engl J Med
. 2015
Jul
;373
(4
):307
–16
.
[PubMed]
0028-479335.
Poortmans
P
, Kouloulias
V
, van Tienhoven
G
, Collette
L
, Struikmans
H
, Venselaar
JL
, et al.; EORTC Radiation Oncology and Breast Cancer Groups
. Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works
. Strahlenther Onkol
. 2006
Oct
;182
(10
):576
–82
.
[PubMed]
0179-715836.
Hennequin
C
, Bossard
N
, Servagi-Vernat
S
, Maingon
P
, Dubois
JB
, Datchary
J
, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy
. Int J Radiat Oncol Biol Phys
. 2013
Aug
;86
(5
):860
–6
.
[PubMed]
0360-301637.
Prescott
RJ
, Kunkler
IH
, Williams
LJ
, King
CC
, Jack
W
, van der Pol
M
, et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial
. Health Technol Assess
. 2007
Aug
;11
(31
):1
–149
.
[PubMed]
1366-527838.
Kunkler
IH
, Williams
LJ
, Jack
WJ
, Cameron
DA
, Dixon
JM
; PRIME II investigators
. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
. Lancet Oncol
. 2015
Mar
;16
(3
):266
–73
.
[PubMed]
1470-2045© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
